NEW YORK, November 28, 2016 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com draws investors'
Last Friday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. ended the session 3.96% lower at $1.94, with a total trading volume of 678,444 shares. The stock is trading 16.08% below its 50-day moving average. Shares of the Company, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 39.54.
On November 11th, 2016, ImmunoGen announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with immune checkpoint inhibition. Mirvetuximab soravtansine is a first-in-class folate receptor alpha (FR?)-targeting ADC and is entering a Phase 3 trial, FORWARD I, as a single agent treatment for platinum-resistant ovarian cancer. Mirvetuximab is also being assessed in combination regimens with Keytruda®, an immune checkpoint inhibitor, as well as Doxil®, carboplatin and Avastin® for both platinum-resistant and platinum-sensitive ovarian cancer in the Phase 1b/2 FORWARD II trial. The Company expects initial data from FORWARD II in mid-2017. The free research report on IMGN is available at:
Los Angeles, California headquartered Puma Biotechnology Inc.'s stock gained 1.73%, to close the day at $47.10. A total volume of 232,323 shares was traded. The Company's shares have gained 12.14% in the past month and are trading 11.10% above their 200-day moving average. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have an RSI of 51.66.
On November 15th, 2016, Puma Biotechnology announced that its lead drug candidate PB272 (neratinib) will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium, December 6th-10th, 2016, in San Antonio, Texas. The complimentary report on PBYI can be downloaded at:
Shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. recorded a trading volume of 571,281 shares at the close of the last trading session. The stock ended the day 4.01% higher at $4.67. Shares of the Company, which develops novel drugs to treat intractable diseases in the US, are trading below their 200-day moving average by 18.68%. Furthermore, Arrowhead Pharmaceuticals' stock has an RSI of 39.55.
On November 10th, 2016, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $10 a share to $8 a share.
On November 14th, 2016, Arrowhead Pharmaceuticals delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its preclinical development program targeting factor XII (F12) for the prophylactic treatment of thromboembolism and hereditary angioedema. These data show advancements being made in the ARC-LPA and ARC-F12 programs and in the development of Arrowhead's proprietary DPCsq[TM] delivery vehicle designed for subcutaneous administration of RNAi therapeutics. Visit us today and download our complete research report on ARWR for free at:
New York headquartered Intra-Cellular Therapies Inc.'s shares finished Friday's session 0.59% higher at $13.66, with a total trading volume of 299,513 shares. The stock has advanced 6.22% in the last one month. The Company's shares are trading below their 50-day moving average by 29.25%. Furthermore, shares of Intra-Cellular Therapies, which discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system, have an RSI of 31.46.
On November 09th, 2016, Intra-Cellular Therapies reported a net loss of $30.3 million, or $0.70 per share (basic and diluted), for Q3 2016 compared to a net loss of $32.2 million, or $0.91 per share (basic and diluted), for Q3 2015. The company's Research and development expenses were $23.9 million for Q3 2016 compared to $28.5 million for Q3 2015. The decrease is primarily due to lower costs associated with the Company's second Phase 3 clinical trial for ITI-007 in patients with schizophrenia, which was completed during Q3 2016. The company's cash and investments totaled $537.8 million at September 30, 2016. This amount included short-term borrowing of $125 million that was repaid in October 2016. The resulting net cash available for operations at September 30th, 2016, was $412.8 million compared to $475.2 million at December 31st, 2015. Get free access to your technical report on ITCI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All